• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Unicycive Therapeutics Inc (UNCY)

Common Shares
Sell: $5.97|Buy: $6.02|Change: 0.70 (-10.49%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent beingdeveloped for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Address




Website

https://www.unicycive.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Unicycive Therapeutics Inc Third Quarter Earnings Results for 20262026-11-12T00:00:00
Unicycive Therapeutics Inc Second Quarter Earnings Results for 20262026-08-14T00:00:00
Unicycive Therapeutics Inc Annual General Meeting for 20262026-06-09T07:00:00
Unicycive Therapeutics Inc First Quarter Earnings Results for 20262026-05-14T00:00:00
Unicycive Therapeutics Inc Annual Report for 20252026-03-31T00:00:00

Previous key dates

NameKey Date
Noble Capital Markets Virtual Presentation2025-12-10T10:00:00
Piper Sandler 37th Annual Healthcare Conference2025-12-03T10:00:00
Unicycive Therapeutics Inc Third Quarter Earnings Results for 20252025-11-12T00:00:00
Guggenheim 2nd Annual Healthcare Innovation Conference2025-11-10T15:30:00
Truist Securities Virtual Fireside Chat2025-09-17T10:00:00
H.C. Wainwright 27(th) Annual Global Investment Conference2025-09-10T08:30:00
Unicycive Therapeutics Inc Second Quarter Earnings Results for 20252025-08-14T00:00:00
H.C. Wainwright 4th Annual Kidney Virtual Conference2025-07-14T11:00:00
Unicycive Therapeutics Inc Annual General Meeting for 20252025-06-09T07:00:00
Noble capital markets 2025 emerging growth virtual equity conference2025-06-04T13:00:00
Lytham Partners Spring 2025 Investor Conference2025-05-29T12:30:00
Unicycive Therapeutics Inc First Quarter Earnings Results for 20252025-05-14T00:00:00
24th Annual Needham Virtual Healthcare Conference2025-04-07T14:15:00
Unicycive Therapeutics Inc Fourth Quarter Earnings Results for 20242025-03-31T00:00:00
Unicycive Therapeutics Inc Annual Report for 20242025-03-31T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.